Team

JEFF GOATER

Jeff Goater was appointed Interim Chief Executive Officer in January 2022, coincident with the transition of John Josey to Chairman of the Board. Jeff is also a member of the Board of Directors of Atavistik Bio and a Venture Partner at The Column Group. Previously, he served as Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline.  Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme.  Previously, Jeff spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy and holds master’s degrees in microbiology/immunology (MS), pathology (MS) and business administration (MBA) from the University of Rochester.  Jeff also currently serves on the boards of Ribon Therapeutics, Surface Oncology, Vaccinex and LogicBio Therapeutics.

MARION DORSCH, PhD

Marion Dorsch brings over 20 years of drug discovery experience in oncology, inflammation and rare genetic diseases to Atavistik Bio. She is an accomplished scientist and senior executive with a proven track record of discovering and advancing innovative therapies to patients. Most recently, Marion served as Chief Scientific Officer at Blueprint Medicines, where she led the Discovery and Translational Medicine teams and oversaw the progression of a strong portfolio of precision medicines. She joined Blueprint Medicines from Agios where she was the Vice President of Biology and responsible for novel target validation, drug discovery, and biomarker strategy across Agios’ portfolio. Prior to Agios, Marion was Director of Cancer Biology at Sanofi Oncology, Group leader in Oncology at the Novartis and part of the Inflammation group at Millennium Pharmaceuticals. During her tenure in biotech and pharma, Marion has made major contributions to the discovery and development of 6 FDA-approved precision medicines: Odomzo (SMO), Kisqali (CDK4/6), Idhifa (IDH2), Tibsovo (IDH1), Ayvakit (KIT/PDGFR) and Gavreto (RET).

Marion received her PhD in Biology from the Free University of Berlin, Germany and was a postdoctoral fellow in the laboratory of Dr. Stephen Goff at Columbia University in New York.

ANINDA KATRAGADDA

Aninda Katragadda is Chief Financial Officer at Atavistik Bio since February 2022. Aninda has more than 25 years of experience in finance leadership roles in the life science industry. Prior to joining Atavistik, Aninda served most recently as Senior Vice President, Finance and Treasurer at Akouos, where she was responsible for all finance, accounting and operations functions from the founding of the company through several private equity financings and successful initial public offering. Prior to Akouos, she held senior finance positions at Voyager Therapeutics and The Medicines Company, and has also consulted most recently at Surface Oncology and Foghorn Therapeutics.  Aninda started her biotechnology finance career at Vertex Pharmaceuticals and public accounting career at PWC.  She holds a BS in Business Administration and Accounting from University of Missouri and earned her CPA in Massachusetts.

MARIA-JESUS BLANCO, PhD

Maria-Jesus Blanco brings over 22 years of experience in drug discovery and development working in biotech and the pharmaceutical industry. Maria joined Atavistik Bio from Sage Therapeutics, where she served as Head of Chemistry and Sr. Director. Maria began her career at Eli Lilly and Company in Indianapolis where she held positions of increasing responsibility over 17 years, including Director of Discovery Chemistry Research & Technologies. Her leadership, creativity and strategic thinking have led to impactful contributions on new chemical modalities, chemical biology, protein-protein interactions, PET ligands, translational research and small molecule therapeutics primarily in neuroscience and oncology. Maria was part of the team that discovered FDA-approved Reyvow (5-HT1F) and has actively contributed to the delivery of 14 compounds to clinical studies.

Maria obtained her BS and PhD degree in Organic Chemistry from the University of Santiago de Compostela, Spain. She held postdoctoral positions at Massachusetts Institute of Technology (MIT) and at University of Strasbourg, France with Nobel Laureate Prof. Sauvage. Maria has >100 scientific publications, presentations, patent and patent applications. She was elected as a member of the executive committee of the ACS National Division of Medicinal Chemistry, being the 2021-22 Program Chair. After contributing as a guest editor to the special issue Women in Medicinal Chemistry, she is currently an associate editor for ACS Medicinal Chemistry Letters. In 2021, she was inducted as an ACS Fellow for her lasting service to chemistry, society, and medicine.

THOMAS RODDY, PhD

Tom Roddy has worked across many areas of the drug discovery pipeline over the past 20+ years, from pre-competitive academic collaborations to post-marketing studies. Previously, he was the Vice President of Metabolism and Proteomics at Agios Pharmaceuticals. During his tenure at Agios, he led the start of the External Innovation function. His career started at Genzyme and he has worked at several other companies such as Novartis Institutes for BioMedical Research, Merck, and Beryllium. He is an internationally recognized analytical scientist and an accomplished scientific team builder and mentor, having led many successful biomarker, analytical, and target discovery teams. He is an author on ~80 publications in research focused on disease biology, pharmacology, and analytical sciences and has been a successful collaborator with leading global academic groups and CROs in the understanding of the mechanisms and physiology of existing and novel metabolism-based therapies. He has made translational contributions to Fabrazyme, Myozyme, Anacetrapib, Idhifa, Tibsovo, Ivosidenib, and Mitapivat.

Tom received his PhD in Chemistry from The Pennsylvania State University, an MS in Chemistry from Villanova University, and a BS in Chemistry from Juniata College.

SHOMIT SENGUPTA, PhD

Shomit Sengupta brings over 10 years of drug discovery experience focused on metabolism and related signaling pathways to Atavistik Bio. He is an accomplished scientist and manager with a strong publication record and experience in both early and late-stage drug development. Most recently, Shomit was an Associate Director at Agios Pharmaceuticals, where he managed teams of scientists responsible for validating new therapeutic targets and evaluating new indications for existing assets for the rare genetic disease portfolio. He joined Agios from Navitor Pharmaceuticals where he was the lead biologist from discovery to IND for a first-in-class modulator of leucine sensing for treatment-resistant depression. Prior to Navitor, Shomit worked on cell pharmacology screening efforts at the Center for the Development of Therapeutics at the Broad Institute, and the development and execution of clinical biomarker assays at Catabasis Pharmaceuticals.

Shomit received his PhD in Biology from the Whitehead Institute at MIT and did his postdoctoral training in the lab of Joan Brugge at Harvard Medical School.

LINDSAY DUHAIME

Lindsay Duhaime is the Head of Operations at Atavistik Bio, leading all operations functions to support the business needs, innovative science, and cultural aspirations of the organization. Lindsay brings over 14 years of experience in the biotech industry, with expertise in lab operations, lab planning & design, strategic planning, finance, culture & employee engagement, and crisis management. Prior to joining Atavistik Bio, Lindsay was the Head of Operations at the Novartis Institutes for Biomedical Research where she supported multiple global departments. Lindsay started her career as a bench scientist, involved in proteomics-based target identification and technology development. During her tenure at Novartis, she transitioned to operations where she held roles of increasing responsibility and scope, including successfully leading teams to support the evolution and strategic growth of several discovery research departments. Lindsay holds a MS in Biochemistry from The George Washington University and a BS in Biochemistry from the University of New Hampshire.

JOHN A. JOSEY, PhD

Dr. Josey joined The Column Group as a Venture Partner in 2020. Previously he served as the President, Chief Executive Officer and a member of the Board of Directors of Peloton Therapeutics, Inc., from 2013 until its acquisition by Merck in 2019. He joined Peloton in 2011 as the first employee in the role of President and Chief Scientific Officer. For over thirteen years, Dr. Josey was employed at Array BioPharma Inc., a company that he helped to build as a member of the founding management team. There he rose to Vice President of Discovery Chemistry. Dr. Josey’s previous experience also includes Amgen, Inc. and the Glaxo Research Institute. He received a BS degree in chemistry from Colorado State University, a PhD in organic chemistry from The University of Texas at Austin, and an MBA from the University of Colorado. He was a Damon Runyon-Walter Winchell Postdoctoral Fellow at the California Institute of Technology.

Board of Directors: Atavistik Bio, Inc. (Chair); Circle Pharma, Inc. (Chair); Day One Biopharmaceuticals, Inc.; Nura Bio, Inc; VHL Alliance

JEFF GOATER

Jeff Goater was appointed Interim Chief Executive Officer in January 2022, coincident with the transition of John Josey to Chairman of the Board. Jeff is also a member of the Board of Directors of Atavistik Bio and a Venture Partner at The Column Group. Previously, he served as Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline.  Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme.  Previously, Jeff spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy and holds master’s degrees in microbiology/immunology (MS), pathology (MS) and business administration (MBA) from the University of Rochester.  Jeff also currently serves on the boards of Ribon Therapeutics, Surface Oncology, Vaccinex and LogicBio Therapeutics.

HELEN HOBBS, MD

Helen H. Hobbs is a physician-scientist and Investigator of the Howard Hughes Medical Institute at the University of Texas Southwestern Medical Center (UTSW) in Dallas Texas. After attending Stanford University and Case Western Reserve Medical School, she trained in internal medicine at Columbia-Presbyterian and UTSW. She joined the faculty of UTSW in 1987 where she is Professor of Internal Medicine and Molecular Genetics. Together with Jonathan C. Cohen, she identified new sequence variations/genes contributing to differences in plasma lipid levels, which led to the development of two new lipid-lowering therapies for the prevention of heart attacks. She also has identified the first and most important genetic difference contributing to susceptibility to fatty liver disease. Gene identification is just the starting point for her studies. She has performed functional studies to elucidate the pathways and processes that are altered by the defective genes she has identified. She is a member of the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. She is on the board of Pfizer Inc. and a Science Partner of the Column Group. Among the prizes she has received are the Breakthrough Prize in Life Sciences, the Grand Prix Award from the Institute of France, and the Harrington Prize for Innovation in Medicine.